Erdafitinib in Patients With Advanced Solid Tumours With FGFR Alterations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
Lancet Oncol 2023 Aug 01;24(8)925-935, S Pant, M Schuler, G Iyer, O Witt, T Doi, S Qin, J Tabernero, DA Reardon, C Massard, A Minchom, I Lugowska, O Carranza, D Arnold, M Gutierrez, H Winter, K Stuyckens, L Crow, S Najmi, C Hammond, S Thomas, A Santiago-Walker, S Triantos, H Sweiti, Y LoriotFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.